Casirivimab/imdevimab
id:
casirivimab-imdevimab-183-14139554
title:
Casirivimab/imdevimab
text:
Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID‑19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron
brand slug:
wiki
category slug:
encyclopedia
description:
Antiviral combination medication
original url:
https://en.wikipedia.org/wiki/Casirivimab/imdevimab
date created:
2020-09-14T18:24:36Z
date modified:
2024-09-07T03:31:14Z
main entity:
{"identifier":"Q99328880","url":"https://www.wikidata.org/entity/Q99328880"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/d/d2/REGN-COV2_binding_SARS-CoV-2_spike_protein.png","width":2048,"height":2048}
fields total:
13
integrity:
16